PT3814341T - Inibidores de recetor erbb - Google Patents
Inibidores de recetor erbbInfo
- Publication number
- PT3814341T PT3814341T PT198005092T PT19800509T PT3814341T PT 3814341 T PT3814341 T PT 3814341T PT 198005092 T PT198005092 T PT 198005092T PT 19800509 T PT19800509 T PT 19800509T PT 3814341 T PT3814341 T PT 3814341T
- Authority
- PT
- Portugal
- Prior art keywords
- receptor inhibitors
- erbb receptor
- erbb
- inhibitors
- receptor
- Prior art date
Links
- 102000001301 EGF receptor Human genes 0.000 title 1
- 108060006698 EGF receptor Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018085998 | 2018-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3814341T true PT3814341T (pt) | 2024-04-11 |
Family
ID=68467752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT198005092T PT3814341T (pt) | 2018-05-08 | 2019-05-08 | Inibidores de recetor erbb |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10822334B2 (pt) |
| EP (2) | EP4410291A3 (pt) |
| JP (1) | JP2024050653A (pt) |
| KR (1) | KR20210013071A (pt) |
| CN (4) | CN111662289A (pt) |
| AR (1) | AR117424A1 (pt) |
| AU (1) | AU2019267959B2 (pt) |
| BR (1) | BR112020022829A2 (pt) |
| CA (1) | CA3099315A1 (pt) |
| DK (1) | DK3814341T3 (pt) |
| ES (1) | ES2977196T3 (pt) |
| MX (2) | MX2020011868A (pt) |
| PT (1) | PT3814341T (pt) |
| TW (2) | TWI811358B (pt) |
| WO (1) | WO2019214634A1 (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3778589B1 (en) * | 2018-04-09 | 2022-05-11 | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. | 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier |
| CN110357858B (zh) | 2018-04-09 | 2022-02-18 | 威尚（上海）生物医药有限公司 | 具有穿过血脑屏障能力的5取代二氟哌啶化合物 |
| TWI811358B (zh) * | 2018-05-08 | 2023-08-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
| DK3853220T3 (da) * | 2018-09-18 | 2024-03-04 | Hoffmann La Roche | Quinazolinderivater som antitumormidler |
| AR117788A1 (es) * | 2019-01-14 | 2021-08-25 | Pi Industries Ltd | Compuestos de fenilamidina 3-sustituida, preparación y uso |
| BR112023021111A2 (pt) | 2021-04-13 | 2023-12-19 | Nuvalent Inc | Composto, composição farmacêutica, método de tratamento de câncer, método para inibir seletivamente her2, método de regulação de um nível de her2, método para aumentar um nível de her2, método de diminuição da fosforilação de her2 |
| EP4399207A1 (en) * | 2021-10-20 | 2024-07-17 | F. Hoffmann-La Roche AG | Crystalline forms of quinazoline derivatives, preparation, composition and use thereof |
| CN114262327B (zh) * | 2021-12-30 | 2023-01-03 | 武汉九州钰民医药科技有限公司 | 一种her2小分子抑制剂图卡替尼的制备工艺 |
| CN114671867B (zh) * | 2022-03-15 | 2023-09-19 | 上海法默生物科技有限公司 | 妥卡替尼中间体7-羟基-[1,2,4]***并[1,5-a]吡啶的制备方法 |
| WO2024133302A1 (en) | 2022-12-22 | 2024-06-27 | Boehringer Ingelheim International Gmbh | Crystalline forms of a her2 inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| GB0126433D0 (en) * | 2001-11-03 | 2002-01-02 | Astrazeneca Ab | Compounds |
| JP2005515176A (ja) * | 2001-11-03 | 2005-05-26 | アストラゼネカ アクチボラグ | 抗腫瘍剤としてのキナゾリン誘導体 |
| GB0504474D0 (en) * | 2005-03-04 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| CN101273033A (zh) * | 2005-09-20 | 2008-09-24 | 阿斯利康(瑞典)有限公司 | 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物 |
| EP1928861B1 (en) * | 2005-09-20 | 2010-11-17 | AstraZeneca AB | 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer |
| PT1971601E (pt) * | 2005-11-15 | 2010-01-26 | Array Biopharma Inc | Derivados de n4-fenil-quinazolina-4-amina e compostos relacionados como inibidores de tirosina quinases receptoras do tipo i erbb para o tratamento de doenças hiperproliferativas |
| TWI811358B (zh) * | 2018-05-08 | 2023-08-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
-
2019
- 2019-05-07 TW TW108115721A patent/TWI811358B/zh active
- 2019-05-07 AR ARP190101206A patent/AR117424A1/es unknown
- 2019-05-07 TW TW112129260A patent/TW202344253A/zh unknown
- 2019-05-08 ES ES19800509T patent/ES2977196T3/es active Active
- 2019-05-08 CA CA3099315A patent/CA3099315A1/en active Pending
- 2019-05-08 CN CN202010657654.7A patent/CN111662289A/zh active Pending
- 2019-05-08 DK DK19800509.2T patent/DK3814341T3/da active
- 2019-05-08 CN CN201980006431.XA patent/CN111587248A/zh active Pending
- 2019-05-08 MX MX2020011868A patent/MX2020011868A/es unknown
- 2019-05-08 PT PT198005092T patent/PT3814341T/pt unknown
- 2019-05-08 AU AU2019267959A patent/AU2019267959B2/en active Active
- 2019-05-08 EP EP24164213.1A patent/EP4410291A3/en active Pending
- 2019-05-08 CN CN202010656946.9A patent/CN111747953B/zh active Active
- 2019-05-08 WO PCT/CN2019/085949 patent/WO2019214634A1/en unknown
- 2019-05-08 BR BR112020022829-0A patent/BR112020022829A2/pt unknown
- 2019-05-08 KR KR1020207034917A patent/KR20210013071A/ko not_active Application Discontinuation
- 2019-05-08 CN CN202010657663.6A patent/CN112266384B/zh active Active
- 2019-05-08 EP EP19800509.2A patent/EP3814341B1/en active Active
-
2020
- 2020-06-24 US US16/910,267 patent/US10822334B2/en active Active
- 2020-09-23 US US17/029,074 patent/US11447492B2/en active Active
- 2020-11-06 MX MX2023008954A patent/MX2023008954A/es unknown
-
2024
- 2024-01-22 JP JP2024007265A patent/JP2024050653A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210009587A1 (en) | 2021-01-14 |
| US10822334B2 (en) | 2020-11-03 |
| CN111747953B (zh) | 2021-05-07 |
| JP2024050653A (ja) | 2024-04-10 |
| EP4410291A3 (en) | 2024-08-14 |
| AR117424A1 (es) | 2021-08-04 |
| CN111587248A (zh) | 2020-08-25 |
| CN111662289A (zh) | 2020-09-15 |
| EP3814341A1 (en) | 2021-05-05 |
| CN112266384A (zh) | 2021-01-26 |
| US11447492B2 (en) | 2022-09-20 |
| ES2977196T3 (es) | 2024-08-20 |
| AU2019267959A1 (en) | 2020-11-26 |
| CN111747953A (zh) | 2020-10-09 |
| AU2019267959B2 (en) | 2024-06-06 |
| WO2019214634A1 (en) | 2019-11-14 |
| KR20210013071A (ko) | 2021-02-03 |
| CN112266384B (zh) | 2022-09-23 |
| TW202015690A (zh) | 2020-05-01 |
| TWI811358B (zh) | 2023-08-11 |
| EP3814341B1 (en) | 2024-03-20 |
| US20200317669A1 (en) | 2020-10-08 |
| CA3099315A1 (en) | 2019-11-14 |
| TW202344253A (zh) | 2023-11-16 |
| BR112020022829A2 (pt) | 2021-02-02 |
| JP2021523159A (ja) | 2021-09-02 |
| MX2023008954A (es) | 2023-08-18 |
| DK3814341T3 (da) | 2024-04-22 |
| EP3814341A4 (en) | 2022-01-05 |
| EP4410291A2 (en) | 2024-08-07 |
| MX2020011868A (es) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | kif18a inhibitors | |
| PT3814341T (pt) | Inibidores de recetor erbb | |
| PT3746424T (pt) | Inibidores de erbb/btk | |
| IL276269A (en) | Aminopyrrolotriazines as kinase inhibitors | |
| GB201911187D0 (en) | Receptor | |
| GB201905552D0 (en) | Antagonists | |
| IL276013A (en) | pi4kiiibeta inhibitors | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | |
| GB201815629D0 (en) | Antagonists | |
| GB201807845D0 (en) | Kinase Inhibitors | |
| ZA202003808B (en) | Erbb/btk inhibitors | |
| GB201910526D0 (en) | Antagonist | |
| GB201909500D0 (en) | Antagonist | |
| IL283413A (en) | Antagonists | |
| IL292104A (en) | egfr inhibitors | |
| EP4076665C0 (en) | EGFR INHIBITORS | |
| IL269414A (en) | Rapar for safetyin taneis | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB201812604D0 (en) | Antagonist compounds | |
| GB201812462D0 (en) | Inhibitors | |
| GB201910865D0 (en) | Antagonist compounds | |
| GB201914388D0 (en) | Kinase inhibitors | |
| GB201904158D0 (en) | Antagonist compounds | |
| GB201804439D0 (en) | Dopamin-b-hydroxylase inhibitors |